Luye Pharma Group Ltd. (HKG:2186)

Luye Pharma Group Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	6,936	4,937	3,239	2,324	2,438	3,865
Short-Term Investments	262	62	1,272	1,247	387.86	109
Trading Asset Securities	1,635	1,504	1,596	1,974	2,684	1,432
Cash & Short-Term Investments	8,833	6,503	6,106	5,544	5,510	5,406
Cash Growth	36.31%	6.50%	10.14%	0.62%	1.92%	39.33%
Accounts Receivable	3,172	2,780	2,355	1,784	1,765	1,553
Other Receivables	-	1,598	320.52	550.76	668.41	253.52
Receivables	3,172	4,378	2,675	2,334	2,434	1,807
Inventory	871.65	911.89	827.86	772.94	746.34	612.3
Prepaid Expenses	-	323.6	94.13	466.54	-	93.7
Restricted Cash	-	-	-	32	31.98	37.47
Other Current Assets	2,811	1,192	999.44	1,636	1,675	2,014
Total Current Assets	15,687	13,308	10,703	10,786	10,397	9,970
Property, Plant & Equipment	5,351	5,339	5,089	4,589	4,203	4,016
Long-Term Investments	2,506	2,492	1,968	1,114	582.2	71.46
Goodwill	1,090	1,012	1,042	1,003	985.41	1,057
Other Intangible Assets	6,703	5,464	4,805	4,448	4,080	3,765
Long-Term Deferred Tax Assets	111.68	163.58	144.59	113.95	133.11	114.74
Long-Term Deferred Charges	-	1,122	1,513	1,536	1,362	1,005
Other Long-Term Assets	583.02	710.96	226.1	658.43	839.37	631.68
Total Assets	32,031	29,612	25,491	24,250	22,582	20,631
Accounts Payable	663.48	689.3	767.19	559.94	570.89	485.26
Accrued Expenses	-	626.1	746.77	686.18	430.41	210.47
Short-Term Debt	6,627	5,118	4,568	4,723	4,740	5,415
Current Portion of Long-Term Debt	2,074	2,447	609.05	2,102	500.62	214.81
Current Portion of Leases	20.18	19.79	18.5	15.25	22.75	13.01
Current Income Taxes Payable	233.14	294.39	200.33	133.2	141.14	308.35
Current Unearned Revenue	15.79	188.26	156.55	72.83	70.99	131.19
Other Current Liabilities	2,305	1,386	1,071	1,195	853.54	455.97
Total Current Liabilities	11,939	10,769	8,138	9,487	7,330	7,234
Long-Term Debt	3,112	2,694	3,176	2,241	4,208	4,327
Long-Term Leases	37.32	42.17	52.15	23.24	19.21	11.73
Long-Term Unearned Revenue	181.51	130.56	172.22	384.44	209.39	185.66
Long-Term Deferred Tax Liabilities	32.38	36.48	47.26	56.03	57.87	74.32
Other Long-Term Liabilities	180.79	181.03	372.65	1,013	1,636	690.76
Total Liabilities	15,489	13,859	11,962	13,208	13,468	12,532
Common Stock	486.11	486.11	486.11	456.95	455.84	417.99
Additional Paid-In Capital	4,250	4,250	4,159	3,077	1,716	1,042
Retained Earnings	-	7,832	7,381	6,667	6,062	6,209
Treasury Stock	-	-	-	-279.56	-279.56	-279.56
Comprehensive Income & Other	9,956	1,587	505.21	254.46	534.04	501.52
Total Common Equity	14,693	14,155	12,531	10,176	8,488	7,891
Minority Interest	1,850	1,599	997.31	865.77	625.78	207.78
Shareholders' Equity	16,543	15,754	13,528	11,042	9,114	8,099
Total Liabilities & Equity	32,031	29,612	25,491	24,250	22,582	20,631
Total Debt	11,871	10,321	8,424	9,105	9,491	9,982
Net Cash (Debt)	-3,038	-3,818	-2,318	-3,560	-3,980	-4,575
Net Cash Per Share	-0.81	-1.01	-0.62	-1.02	-1.16	-1.43
Filing Date Shares Outstanding	3,762	3,762	3,762	3,550	3,541	3,183
Total Common Shares Outstanding	3,762	3,762	3,762	3,550	3,541	3,183
Working Capital	3,748	2,539	2,565	1,299	3,066	2,736
Book Value Per Share	3.91	3.76	3.33	2.87	2.40	2.48
Tangible Book Value	6,900	7,678	6,684	4,724	3,423	3,070
Tangible Book Value Per Share	1.83	2.04	1.78	1.33	0.97	0.96
Buildings	-	2,613	2,013	1,707	1,602	1,455
Machinery	-	4,119	3,636	3,408	3,031	2,718
Construction In Progress	-	884.73	1,381	1,081	832.93	864.86
Leasehold Improvements	-	59.49	54.98	43.93	40.26	25.4

Source: S&P Global Market Intelligence. Standard template. Financial Sources.